Leerink Partners

Founded in 1995 by Jeffrey Leerink, the firm built its franchise around healthcare and life sciences. SVB Financial acquired the business for $280 million in early 2019; after SVB Securities was sold to a management group in 2023, the business returned to the Leerink Partners name and became independently owned.

Leerink advises biopharma, medical technology, diagnostics, healthcare technology and healthcare-services companies on M&A, IPOs, follow-on offerings, private placements and other strategic transactions. It also provides institutional equity research, sales and trading, and alternative-equities services.

Its strongest differentiator is sector specialization: analysts cover more than 300 healthcare companies, while the investment-banking platform combines scientific and industry expertise with capital-markets execution. The firm has expanded its M&A capabilities under Tom Davidson and ranked first in 2025 for both US biopharma and broader healthcare stock-deal market share, according to Dealogic data reported by The Boston Globe.